AbbVie Inc. (ABBV)
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
AbbVie NYSE: ABBV told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development.
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for both earnings and sales and the guidance for 2026 revenues and earnings was also raised.
10 Years, Zero Regrets: The Dividend Stocks I Keep Buying
Dividend stocks can be a pillar for long-term investing, generating passive income and offering stability even during tough environments.
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.
AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried
AbbVie delivered a strong earnings beat this week, driven by its immunology portfolio. WSJ's David Wainer explains why Wall Street is still jittery.
AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings
AbbVie's price might have been sluggish in 2026 so far, but can the latest results change anything? Yes and no. No, because there's acquisition talk doing the rounds, which can be an earnings drag for now, even though it can be positive for revenues. Yes, because the latest results for Q1 2026 are good, with double-digit percent revenue growth and a healthy adjusted EPS rise too. The market multiples also look improved.
Price Prediction: Why AbbVie's Post-Humira Pivot Makes It a Strong Buy
Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but encouraging Q1 earnings report.
AbbVie Inc. (ABBV) Q1 2026 Earnings Call Transcript
AbbVie Inc. (ABBV) Q1 2026 Earnings Call Transcript
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?
AbbVie's NYSE: ABBV share price has been under pressure due to rising costs and concerns that its post-Humira days won't be as robust. However, the stock price decline put the market in a position to trigger a trend-following signal, which happened after its Q1 earnings results.
AbbVie (ABBV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
